Additionally, the 36-month beta value for TSBX is 1.38. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for TSBX is 17.23M and currently, short sellers hold a 2.19% ratio of that float. The average trading volume of TSBX on April 28, 2025 was 190.72K shares.
TSBX) stock’s latest price update
Turnstone Biologics Corp (NASDAQ: TSBX) has experienced a rise in its stock price by 9.72 compared to its previous closing price of 0.32. However, the company has seen a gain of 6.06% in its stock price over the last five trading days. globenewswire.com reported 2025-03-28 that SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) — Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer (“SITC”) Annual Meeting.
TSBX’s Market Performance
Turnstone Biologics Corp (TSBX) has seen a 6.06% rise in stock performance for the week, with a -12.50% decline in the past month and a -23.91% plunge in the past quarter. The volatility ratio for the week is 12.01%, and the volatility levels for the past 30 days are at 10.97% for TSBX. The simple moving average for the past 20 days is -3.54% for TSBX’s stock, with a -52.65% simple moving average for the past 200 days.
Analysts’ Opinion of TSBX
Many brokerage firms have already submitted their reports for TSBX stocks, with Piper Sandler repeating the rating for TSBX by listing it as a “Neutral.” The predicted price for TSBX in the upcoming period, according to Piper Sandler is $0.40 based on the research report published on February 05, 2025 of the current year 2025.
TSBX Trading at -7.32% from the 50-Day Moving Average
After a stumble in the market that brought TSBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.68% of loss for the given period.
Volatility was left at 10.97%, however, over the last 30 days, the volatility rate increased by 12.01%, as shares sank -14.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.53% lower at present.
During the last 5 trading sessions, TSBX rose by +6.06%, which changed the moving average for the period of 200-days by -84.72% in comparison to the 20-day moving average, which settled at $0.3629. In addition, Turnstone Biologics Corp saw -29.56% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TSBX
The total capital return value is set at -2.27. Equity return is now at value -108.87, with -92.63 for asset returns.
Based on Turnstone Biologics Corp (TSBX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -56.72.
Currently, EBITDA for the company is -72.49 million with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.17.
Conclusion
In conclusion, Turnstone Biologics Corp (TSBX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
